Drug intelligence / Profile preview

ELU507

Development stage: Preclinical
Lead developer: Eluciderm
Modality: Small Molecules
Administration: Inhalation

Overview

ELU507 is an investigational small molecule therapeutic being developed by Eluciderm, Inc. for the treatment of pulmonary fibrosis. Designed for administration via inhalation, the drug is intended to deliver treatment directly to the lung tissue to address fibrotic progression. As of early 2024, ELU507 is in the preclinical stage of development. While Eluciderm's core technology platform generally focuses on activating the body's regenerative mechanisms through the modulation of signaling pathways such as Wnt, the specific molecular target for ELU507 has not been publicly disclosed.

Beyond the preview

Go deeper on ELU507.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELU507.

Explore the full profile